(3S,4R)-3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide,
ABT-494,
upadacitinib,
Upadacitinib,
1310726-60-3,
ABT-494,
UNII-4RA0KN46E0,
4RA0KN46E0,
Upadacitinib, ABT-494,
Upadacitinib (USAN/INN),
Upadacitinib [USAN:INN],
ABT494,
GTPL9246,
SCHEMBL9991056,
CHEMBL3622821,
ABT 494,
BCP19011,
EX-A1628,
MFCD30502663,
AKOS030567686,
CS-6150,
SB19218,
AC-30326,
HY-19569,
J3.590.729G,
D10994,
(3S,4R)-3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2- trifluoroethyl)pyrrolidine-1-carboxamide,
(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide,
1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-,
ACN-052823,
(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide,